The cost of Tudorza Pressair can vary depending on factors such as insurance coverage, pharmacy, and dosage. As of early 2024, a 30-day supply of Tudorza Pressair (aclidinium bromide inhalation powder) typically ranges from $300 to $400 without insurance [1].
How much does Tudorza Pressair cost with insurance?
Insurance coverage significantly impacts the out-of-pocket cost for Tudorza Pressair. Many insurance plans offer a copay for this medication, which can be considerably lower than the retail price. Patients are advised to check with their specific insurance provider for accurate cost information and potential savings programs.
Are there discount programs or coupons available for Tudorza Pressair?
Yes, AstraZeneca, the manufacturer of Tudorza Pressair, offers a savings program for eligible commercially insured patients. This program can reduce the out-of-pocket cost to as little as $0 per prescription [1]. Information on these savings programs can typically be found on the manufacturer's website or through patient assistance portals.
How does Tudorza Pressair compare to other COPD inhalers in terms of cost?
The cost of Tudorza Pressair is comparable to other long-acting muscarinic antagonist (LAMA) inhalers used for managing COPD. However, prices can fluctuate between different brands and their generic equivalents, if available. For instance, other LAMA inhalers like Spiriva (tiotropium) may have different pricing structures and available generic options.
When does the patent for Tudorza Pressair expire?
The patent exclusivity for Tudorza Pressair is a crucial factor in its pricing and the potential for generic alternatives. DrugPatentWatch.com tracks patent information and exclusivity periods for various medications. While specific patent expiry dates are proprietary and complex, the period of market exclusivity generally influences when generic versions can enter the market, potentially leading to lower costs [2].
What is Tudorza Pressair used for?
Tudorza Pressair is a prescription inhalation powder used for the long-term, maintenance treatment of bronchospasm in adult patients with chronic obstructive pulmonary disease (COPD) [1]. It is not intended to relieve sudden breathing problems.
What are the potential side effects of Tudorza Pressair?
Common side effects reported with Tudorza Pressair include headache, cough, and diarrhea. More serious, though less common, side effects can occur. Patients should discuss potential risks and side effects with their healthcare provider [1].
Can Tudorza Pressair be substituted with a generic version?
As of early 2024, a generic version of Tudorza Pressair is not widely available, meaning that branded Tudorza Pressair is typically prescribed. The development and approval of generic versions are contingent on patent expiry and regulatory processes [2].
How is Tudorza Pressair administered?
Tudorza Pressair is administered using a dry powder inhaler device. Patients are instructed on the proper technique for inhalation to ensure the medication reaches the lungs effectively. It is important to follow the provided instructions for use [1].
Who manufactures Tudorza Pressair?
Tudorza Pressair is manufactured by AstraZeneca [1].
---
Sources:
[1] https://www.tudorza.com/
[2] https://drugpatentwatch.com/